Open Access
Drug repositioning in Alzheimer’s disease
Anne Corbett1,*,Gareth Williams1,Clive Ballard1
Wolfson Centre for Age-Related Diseases, King’s College London, London SE1 1UL
DOI: 10.2741/S432 Volume 7 Issue 1, pp.184-188
Published: 01 June 2015
(This article belongs to the Special Issue The polyhedral aspects of dementia)
*Corresponding Author(s):  
Anne Corbett

Drug repositioning offers an innovative approach to drug discovery with great potential in the field of Alzheimer’s Disease and dementia therapeutics. Investigation of licensed compounds enables processing through the drug discovery pipeline in a rapid and cost-effective manner. A growing body of evidence supports the translation of priority compounds to be taken forward to clinical trials, based on established and proposed mechanisms of action. A number of drugs have already entered clinical trial following repositioning, and novel technologies have been created to enable high-throughput screening. This review discusses the novel approaches that build on transcriptional signature profiling to support repositioning in AD, and the novel candidate drugs that are emerging from this exciting new technique.

Key words
Alzheimer’s, Repositioning, Transcriptional,Signature, Database, Treatment, Review
Share and Cite
Anne Corbett, Gareth Williams, Clive Ballard. Drug repositioning in Alzheimer’s disease. Frontiers in Bioscience-Scholar. 2015. 7(1); 184-188.